Alexander Fleming, MD

Dr. Alexander Fleming is Founder and Executive Chairman of Kinexum, a company of professionals from across the world with diverse expertise in developing drugs, biotech products, medical devices and digital health technologies. He is also President and co-founder of Kitalys Institute. Dr. Fleming received his M.D. and internal medicine training from Emory, fellowship training in endocrinology at Vanderbilt and metabolism at National Institutes of Health, where he was a senior fellow.

At the US Food and Drug Administration from 1986-98, led many landmark drug and biotech approvals and innovations as well as represented the Agency at the International Conference on Harmonization (ICH) and World Health Organization.

Dr. Fleming has frequently authored scientific articles, books, and book chapters. He has been a member of many corporate and advisory boards to academic and commercial institutions and professional societies. He serves on the joint technology working groups of the European Association for the Study of Diabetes and American Diabetes Association.

Dr. Fleming coined the term, Metabesity, which refers to the constellation of chronic diseases, cancer, and the aging process itself, all which share common metabolic root causes and potential for shared preventions. He organized the first Congress on Metabesity in London in October 2017, which has since been followed by annual conferences in October. Dr. Fleming founded in 2020 the not-for-profit Kitalys Institute as a means of producing Metabesity conferences and advancing all measures that can improve health and healthspan.